Medigene präsentiert auf folgenden wissenschaftlichen Konferenzen
Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard) ein immunonkologisches Plattformunternehmen…
Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard) ein immunonkologisches Plattformunternehmen…
- Automated in vitro testing could reveal better neoantigens that activate more effective killer T cell responses - Two…
The Executive Management Board of Medigene AG (FSE: MDG1, Prime Standard, TecDAX) with the approval of the Company's Sup…
- Synergies between the recombinant T cell technologies of Medigene and self-delivering RNAi technologies from RXi Pharm…
Monetization of last remaining legacy product essentially completes Medigene's transformation into a pure-play, clinical…
. - Shareholders approve all resolutions with a high majority - Dr. Keith Manchester, Ronald Scott and Dr. Gerd Zettlme…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced the appointment of eight leading experts to its new immu…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX), will demonstrate the use of its automated high-throughput screening (HT…
Growing revenues from core business immunotherapies, clinical trial application for second immunotherapy submitted, fina…
Prof. Dolores Schendel, CEO and CSO of Medigene AG (MDG1, Frankfurt, Prime Standard), will present a new approach to dev…